These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7480528)

  • 1. The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia?
    Andreassen OA; Jørgensen HA
    Psychopharmacology (Berl); 1995 Jun; 119(4):474-6. PubMed ID: 7480528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
    Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
    Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment.
    Andreassen OA; Jørgensen HA
    Life Sci; 1995; 57(24):2263-72. PubMed ID: 7475980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
    Shoham S; Mazeh H; Javitt DC; Heresco-Levy U
    Brain Res; 2004 Apr; 1004(1-2):142-7. PubMed ID: 15033429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
    Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
    Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
    Hashimoto T; Ross DE; Gao XM; Medoff DR; Tamminga CA
    Psychopharmacology (Berl); 1998 May; 137(2):107-12. PubMed ID: 9629996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
    Meshul CK; Andreassen OA; Allen C; Jørgensen HA
    Psychopharmacology (Berl); 1996 Jun; 125(3):238-47. PubMed ID: 8815959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallels between behavioral and neurochemical variability in the rat vacuous chewing movement model of tardive dyskinesia.
    Bachus SE; Yang E; McCloskey SS; Minton JN
    Behav Brain Res; 2012 Jun; 231(2):323-36. PubMed ID: 22503783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
    Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
    Egan MF; Hyde TM; Kleinman JE; Wyatt RJ
    Psychopharmacology (Berl); 1995 Jan; 117(1):74-81. PubMed ID: 7724705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
    Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
    Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.
    Andreassen OA; Aamo TO; Jøorgensen HA
    Br J Pharmacol; 1996 Oct; 119(4):751-7. PubMed ID: 8904651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
    Andreassen OA; Ferrante RJ; Aamo TO; Beal MF; Jørgensen HA
    Neuroscience; 2003; 122(3):717-25. PubMed ID: 14622915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
    Van Kampen JM; Stoessl AJ
    Neuroscience; 2000; 101(3):629-35. PubMed ID: 11113312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
    Turrone P; Remington G; Kapur S; Nobrega JN
    Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration.
    Andreassen OA; Meshul CK; Moore C; Jørgensen HA
    Psychopharmacology (Berl); 2001 Aug; 157(1):11-9. PubMed ID: 11512038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.